We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
AGI | LSE:AGI | London | Ordinary Share | IE00B0YT0Q82 | ORD EUR0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.25 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
29/6/2011 08:33 | ok fair enough - best of luck with your investment ;) m | maurillac | |
29/6/2011 08:30 | I hold shares here maurillac. My posts are not really intended to you but MM2 | minime5 | |
29/6/2011 08:29 | minime i hardly think that my one posting above constitutes "moaning constantly" ! btw what is your interest here ? do you hold some shares or just looking for someone to fall out with ? m | maurillac | |
29/6/2011 07:52 | Well if you have spoken to the management then sit tight and stop moaning or sell out!! BTW ramping this every 5 mins on the cr thread is not going to get this noticed! | minime5 | |
29/6/2011 07:38 | This is from share tip website www.watshot.com 8 days ago (similar to AGI, they tipped MOS at 4p last year): AGI Therapeutics (AGI) - Trading below net cash Drug developer AGI Therapeutics is currently valued at £2.6 million, well below its cash pile of $10 million (as at 31st December 2010). The firm concentrates its efforts in the area of specialty indications with unmet medical needs, with particular focus on treatments for conditions which qualify for Orphan Drug status (i.e. those drugs that are applicable for significant competitive advantages such as exclusivity periods, mainly due to the critical nature of the disease). The firm recently identified a promising new lead product candidate, AGI-350, (described as "a novel presentation of an existing marketed drug which AGI will develop to treat a significant unmet medical need in the critical care setting") for which a programme of pre-clinical testing has commenced. "AGI-350 is specifically formulated to allow effective and efficient delivery of the drug directly to the lung to treat a life-threatening, lung-related, condition. There are currently no formulations of the drug available for inhaled delivery, and AGI believes that AGI-350 will represent the first such approved use of the drug to treat the target critical care population." There are currently major changes underway in the pharmaceutical industry, notably the reduction in large pharma R&D budgets, that will see small biotech come under increasing scrutiny, both from the majors and the market in general. Tucking away a few of these might be a very rewarding punt over the next couple of years or so. The cash burn is around $3 million a year so plenty of space for interest to build here. | christianf12 | |
29/6/2011 07:36 | Only 75k available at 4.9p so any real buying pressure would see these multibag. | christianf12 | |
29/6/2011 07:21 | yes. not the only co on aim where the bod seem content to just draw their salaries and appear to lack the gumption to push the business/share price forward. that said if that director still holds those shares he is sat on a bloody big loss - he shouldn`t be lacking motivation ! i really cant believe that the share price will continue to sit here for too long without attracting interest from somebody. patience is a virtue ... m | maurillac | |
28/6/2011 15:13 | cf12 i agree with your comments above but it seems like im the only one at the moment ! aim is stuffed at the moment generally. lets hope that agi bucks the current trend before too long. m | maurillac | |
28/6/2011 14:58 | This is the company AGI have a collaboration with developing AGI-350: | christianf12 | |
27/6/2011 11:55 | AGI have retained losses of $71,150,000. That works out at about £45 million. Under retained deficit in condensed balance sheet Current market cap is £3 million. Wonder what type of premium we would get from someone wanting to take advantage of the tax losses. Pretty good shield there. This company must be worth at least £10-15 million to someone. It has cash of £6 million straight away. £15 million market cap would be over 22pps. | christianf12 | |
27/6/2011 11:34 | HTT rumoured to be a reverse takeover target. I would think AGI must be one also. 9pps of cash, no debt and all those tax losses to utilise. Would get a decent premium from 5p thats for sure. | christianf12 | |
23/6/2011 08:34 | That looks like the end of the cheap shares in Sea - should see this double now on receipt of cash next week. Market played a great game collecting shares from PI's between 26 and 30p. | cammy3 | |
23/6/2011 07:32 | yes the spread is a problem for the day & t traders ;) m | maurillac | |
22/6/2011 20:28 | I don't I'm afraid, although I do know it's dirt cheap. Can't believe the lack of interest here, it will probably have to multibag before the herd start piling in thinking they are on to the next winner. Shouldn't be long then : ) | christianf12 | |
22/6/2011 11:54 | SEA is the biggest nil brainer I have seen in a long while! | christianf12 | |
22/6/2011 10:08 | Hopefully the same time AGI are at 15-20p : ) You got any in here yet? I just took some more SEA, up to 200k now. Nil brainer them at 30-35p. | christianf12 |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions